The FDA Is Using ‘Fresh’ Aborted Baby Body Parts To Experiment On Mice

Shutterstock/ Eric Isselee

Daily Caller News Foundation logo
Grace Carr Reporter
Font Size:

The U.S. Food and Drug Administration (FDA) signed a July 25 contract with Advanced Bioscience Resources, Inc. (ABR) to use aborted baby body parts to continue its ongoing research on mice.

The FDA requires “fresh human tissues” to keep up its research on the human immune system by injecting mice with fetal tissue to “humanize” the rodents, CNS News reported Tuesday.

(U.S. Food And Drug Administration)

The FDA signed the year-long contract with ABR, a non-profit California fetal collection company. The contract allocates $15,900 toward the company’s research, according to the General Services Administration’s federal contract database.

The contract renews research that ABR has been performing for years. It isn’t known, however, if ABR has received fetal tissue from abortions performed at Planned Parenthood clinics, Politico reported in August 2015. Planned Parenthood maintains it doesn’t sell fetal tissue, but undercover videos from the Center for Medical Progress show otherwise. (RELATED: Planned Parenthood Video Exposers Fined $200,000)

The National Institutes of Health (NIH) has paid ABR $257,000 since 2009, according to Politico. The FDA has also paid ABR roughly $73,000 since 2009, mostly for thymus and liver tissue.

“Students for Life condemns the wanton disregard for human life that the FDA is displaying. The FDA was established to protect Americans not exploit them,” Students for Life president Kristan Hawkins said in a Tuesday statement.

“There is no excuse for anyone, much less the taxpayer funded federal government to enter into contracts that prop up this gruesome practice. Such contracts should be immediately terminated and the baby body parts trafficking industry shut down,” March for Life president Tom McClusky also said in a statement Tuesday.

Follow Grace on Twitter.

Content created by The Daily Caller News Foundation is available without charge to any eligible news publisher that can provide a large audience. For licensing opportunities of our original content, please contact